adrenergic agonist eyedrop
Noun: A specific type of medicinal eye drop used primarily to treat glaucoma. It works by activating adrenergic receptors, leading to two main effects: a reduction in the production of the fluid (aqueous humor) inside the eye and an increase in the drainage of this fluid out of the eye via a specific pathway (the uveoscleral pathway). The combined result is a lowering of the elevated pressure inside the eye (intraocular pressure).
This term is used in medical and pharmaceutical contexts to describe a precise class of glaucoma medication. It is a technical compound noun. - The ophthalmologist prescribed an adrenergic agonist eyedrop to manage my open-angle glaucoma. - Compared to other classes of eyedrops, adrenergic agonist eyedrops have a distinct mechanism of action.
- The patient's intraocular pressure decreased significantly after beginning treatment with an adrenergic agonist eyedrop.
- Common side effects of adrenergic agonist eyedrops can include ocular redness and stinging upon application.
- The term is often used in comparative discussions of glaucoma therapies: "Adrenergic agonist eyedrops are typically considered when a patient does not respond adequately to first-line prostaglandin analogs."
- Adrenergic agonist (noun): The broader class of drugs that stimulate adrenergic receptors; can be administered in forms other than eyedrops (e.g., injections, oral medications).
- Antiglaucoma eyedrop (noun): A general term for any eye drop used to treat glaucoma, which includes adrenergic agonists, prostaglandin analogs, beta-blockers, etc.
- Brimonidine (noun): A specific example of a commonly prescribed adrenergic agonist eyedrop.
- Adrenoceptor agonist eyedrop (noun, technical synonym)
- Alpha-agonist eyedrop (noun, more specific, as most ophthalmic adrenergic agonists target alpha receptors)
This is a highly specific medical term with a single, precise meaning related to a treatment for glaucoma. It is not used in general or figurative language.
- a treatment for glaucoma; the eyedrops reduce intraocular pressure by decreasing the production of aqueous humor and increasing its drainage through the uveoscleral pathway